A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.
Background Data on cardiorespiratory fitness (CRF) in psoriatic arthritis (PsA) are scarce. This study aimed to determine the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback